Ponzetto A, Pellicano R, Leone N, Cutufia M A, Turrini F, Grigioni W F, D'Errico A, Mortimer P, Rizzetto M, Silengo L
Department of Gastroenterology, Hospital San Giovanni Battista, Torino, Italy.
Med Hypotheses. 2000 Feb;54(2):275-7. doi: 10.1054/mehy.1999.0987.
Since it has been shown that Helicobacter hepaticus causes both chronic hepatitis and hepatocellular carcinoma (HCC) in mice, it is suggested that differences in the progression of chronic hepatitis C may be due to a cofactor stemming from co-infection by bacteria, especially Helicobacter pylori, and/or other Helicobacter species. An assessment was made of the prevalence of H. pylori infection in HCV-positive cirrhotic patients. The presence of Helicobacter species (spp). was evaluated in resected liver tissue from HCC patients. Serum anti-H. pylori IgG antibodies were determined in 70 males with a clinical and/or histological diagnosis of cirrhosis and HCV infection and in 310 age-matched male blood donors. The prevalences of H. pylori antibody were 77% (54/70) and 59% (183/310) (P 0.004). Primers identifying 26 Helicobacter species were used to determine the presence of the genomic 16S rRNA of this genus in liver tissue resected from 25 cirrhotic HCC patients. Genomic sequences corresponding to H. pylori and H. pullorum were identified in 23 of these 25 livers. Together, these findings support the proposal that H. pylori is implicated in the pathogenesis and progression of cirrhosis, particularly in HCV-infected individuals. Involvement of Helicobacter spp. in HCC also seems highly possible.
由于已证明肝螺杆菌可在小鼠中引发慢性肝炎和肝细胞癌(HCC),因此有人提出,慢性丙型肝炎进展存在差异可能是由于细菌(尤其是幽门螺杆菌)和/或其他螺杆菌属共感染所产生的一种辅助因子所致。对HCV阳性肝硬化患者中幽门螺杆菌感染的患病率进行了评估。在HCC患者切除的肝组织中评估了螺杆菌属的存在情况。测定了70名临床诊断和/或组织学诊断为肝硬化且感染HCV的男性以及310名年龄匹配的男性献血者血清中的抗幽门螺杆菌IgG抗体。幽门螺杆菌抗体的患病率分别为77%(54/70)和59%(183/310)(P<0.004)。使用可识别26种螺杆菌的引物来确定从25例肝硬化HCC患者切除的肝组织中该属基因组16S rRNA的存在情况。在这25例肝脏中的23例中鉴定出了与幽门螺杆菌和鸡螺杆菌相对应的基因组序列。这些研究结果共同支持了幽门螺杆菌与肝硬化的发病机制及进展有关的观点,尤其是在HCV感染个体中。螺杆菌属参与HCC发病似乎也很有可能。